The appointment of Stephen Lemieux as CFO of Edesa Biotech is likely to have a positive short-term impact on the company's stock price. Lemieux's extensive experience in the healthcare and biopharmaceutical sectors, including financial planning, licensing, and mergers & acquisitions, will be valuable for Edesa as it continues to grow and develop its clinical pipeline.